Insmed (NASDAQ: INSM) reported Q1 EPS of ($1.06), $0.17 better than the analyst estimate of ($1.23). Revenue for the quarter came in at $75.5 million versus the consensus estimate of $78.51 million.

GUIDANCE:

Insmed sees FY2024 revenue of $340-360 million, versus the consensus of $354.7 million.

For earnings history and earnings-related data on Insmed (INSM) click here.